Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solara Active Pharma Sciences's ROE % for the quarter that ended in Jun. 2026 was 5.21%. Solara Active Pharma Sciences's PB Ratio for the quarter that ended in Jun. 2026 was N/A.
Solara Active Pharma Sciences's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was N/A.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences ROE % Adjusted to Book Value Chart
BOM:541540 vs ZTS: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solara Active Pharma Sciences ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Solara Active Pharma Sciences's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
Solara Active Pharma Sciences (BOM:541540) has a ROE % Adjusted to Book Value of 0.00% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Solara Active Pharma Sciences and its competitors.
Is Solara Active Pharma Sciences' ROE % Adjusted to Book Value too high?
Solara Active Pharma Sciences' current ROE % Adjusted to Book Value is 0.00%. Overall, Solara Active Pharma Sciences has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' ROE % Adjusted to Book Value compare to ZTS?
Solara Active Pharma Sciences' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Solara Active Pharma Sciences and its competitors. Solara Active Pharma Sciences's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Based on GuruFocus' analysis, Solara Active Pharma Sciences (BOM:541540) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹569.84, compared to a current price of ₹502.15 — trading 11.9% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Solara Active Pharma Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Solara Active Pharma Sciences (BOM:541540), the current ROE % Adjusted to Book Value is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solara Active Pharma Sciences (BOM:541540) Overvalued in 2026?
Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be undervalued.
The current stock price of ₹502.15 is trading 11.9% below its estimated GF Value™ of ₹569.84.
GuruFocus considers Solara Active Pharma Sciences to be Modestly Undervalued.
Key valuation signals for BOM:541540:
ROE % Adjusted to Book Value: 0.00%
GF Value™: ₹569.84 vs. price of ₹502.15 (11.9% below fair value)
No single metric tells the full story. See the BOM:541540 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
69GF Score
Get the complete analysis for BOM:541540
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:541540 has been successfully added to your 
